Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours - Trial NCT02582697

Name: Clinical Trial NCT02582697
Creator: University of Sydney
Keywords: Germ Cell Tumor, Bleomycin (active name: Bleomycin Sulfate), Phase 3, drug, clinical trial, Australia,New Zealand,United States of America

Access comprehensive clinical trial information for NCT02582697 through Pure Global AI's free database. This Phase 3 trial is sponsored by University of Sydney and is currently Recruiting. The study focuses on Germ Cell Tumor. Target enrollment is 500 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database

840K+ Trials

NCT02582697

Phase 3

Recruiting

drug

Trial Details

ClinicalTrials.gov • NCT02582697

View on ClinicalTrials.gov

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Study Focus

Disease/Condition

Germ Cell Tumor

Drug/Device/Intervention

Bleomycin (active name: Bleomycin Sulfate)

Study Type

Interventional

Intervention Type

drug

Sponsor & Location

Primary Sponsor

University of Sydney

Location

New York,Newcastle,St Leonards,Sydney,Sydney,Sydney,Sydney,Sydney,Sydney,Tweed Heads,Wahroonga,Brisbane,South Brisbane,Woolloongabba,Adelaide,Bedford Park,Hobart,Box Hill,East Melbourne,Heidelberg,St , Australia,New Zealand,United States of America

Timeline & Enrollment

Phase

Phase 3

Start Date

Feb 01, 2014

End Date

Jul 01, 2023

Enrollment

500 participants

Primary Outcome

Progression-free survival (disease progression or death)

Summary

The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours.

ICD-10 Classifications

Malignant neoplasms

Malignant neoplasm: Jejunum

Malignant neoplasm: Prepuce

Malignant neoplasm: Female genital organ, unspecified

Malignant neoplasm: Vulva, unspecified

Data Source

Registry

ClinicalTrials.gov

Trial ID

NCT02582697

Type

Non-Device Trial